INTRODUCTION
With an overall 5 year mortality of 50%, congestive heart failure (CHF) is still associated with a poor prognosis. 1 Sleep disordered breathing (SDB) is common in patients with CHF, with approximately a third predominantly having obstructive sleep apnoea (OSA) and another third predominantly having central sleep apnoea with CheyneeStokes respiration (CSA). 2 3 Moreover patients with CHF who have SDB have increased mortality rates compared with those who do not. 4 Whereas in OSA complete cessation of airflow (apnoeas) and/ or discernible reduction in airflow (hypopnoeas) is due to an upper airway collapse, CSA is recognised as a control dysfunction-related disease, an expression of respiratory instability. 5e7 In patients with CHF with CSA, heart failure therapy is the suggested first-line treatment, not only improving CHF but also reducing CSA effectively. 8 OSA does not respond to heart failure therapy. Thus, the European Society of Cardiology (ESC) recommends a specific continuous positive airway pressure (CPAP) ventilation treatment in patients with CHF with OSA, which has proven to have a positive prognostic impact in these patients. 9 However, not all patients respond to CPAP therapy, for example due to unresolved mask leaks or unsatisfactory positive airway pressure titration. 10 Some patients even develop CheyneeStokes respiration during CPAP administration, a finding labelled as complex sleep apnoea (complexSA). 11 In heart failure patients, complexSA, though apparent in clinical practice, has never yet been investigated systematically.
The aim of this study was to investigate the prevalence and characteristics of patients with CHF with complexSA compared with patients with pure OSA, defining predictive factors for complexSA, and evaluating therapeutic effects of adaptive servoventilation on heart failure and SDB parameters.
MATERIALS AND METHODS Patients
Between July 2003 and September 2009, 941 consecutive patients with moderate to severe OSA (apnoeaehypopnoea index (AHI) $15/h) underwent CPAP introduction. In total, 225 presented with stable CHF (left ventricular ejection fraction (LVEF) <45%, New York Heart Association (NYHA) class $II), and were included in a prospective registry. Of those, 192 patients (85.3%) were eligible to be included in this study. Exclusion criteria were current treatment for SDB (8 patients) , evidence of significant pulmonary disease or hypercapnia (partial pressure of CO 2 (pCO 2 ) >45 mm Hg; 3 patients), pregnancy, acute coronary syndrome or acute myocardial decompensation within 3 months (22 patients). Some of the patients included also participated in other studies. ComplexSA was defined as $15 episodes of central apnoea or periodic breathing per hour during CPAP titration and <10% of events being obstructive. All patients undergoing CPAP titration had extensive baseline tests of cardiorespiratory function, described below. Patients diagnosed with complexSA were offered adaptive servoventilation therapy and were reassessed at 3 monthly intervals (figure 1). The last assessment (mean 1464 months) was used to assess changes with adaptive servoventilation therapy. If patients underwent cardiac surgery or invasive procedures (eg, percutanous coronary intervention) or heart failure medication changed (except for dosage adaption) the last assessment prior to the intervention was defined as the end point. Data from patients who died during follow-up were not analysed. All patients gave written informed consent, and the study was approved by the Ethical Review Board of the Ruhr University Bochum.
Sleep studies
Sleep studies were performed by either in-hospital cardiorespiratory polygraphy (Embletta; Embla, Amsterdam, The Netherlands) or polysomnography (N7000/S7000; Embla) as described previously. 12 13 SDB was defined in accordance with a modified version of the 2007 AASM (American Academy of Sleep Medicine) criteria for scoring respiratory events and the SERVE-HF trial study protocol. 14 15 In summary, apnoea was defined by a >90% reduction from baseline to peak amplitude of the signal from nasal cannula (pressure), lasting $10 s, while hypopnoea was defined as a $30% reduction in flow and a $3% desaturation from pre-event baseline for >10 s. Obstructive versus central hypopnoeas were determined on the presence/ absence of inspiratory flow limitation and/or paradoxical abdominal/thoracic movements. CheyneeStokes respiration was defined as at least three episodes of continuous cycles of waxing and waning tidal volumes with periods of hyperventilation separated by central apnoeas or hypopnoeas. If nasal pressure was not available (therapy introduction), XFlow complementary flow signal (sum of the amplitudes of the thoracic and abdominal movements) was referred to instead.
Continuous positive airway pressure
In this study an automatic positive airway pressure (APAP) device (S8 AutoSet Spirit II; ResMed, Martinsried, Germany) was used. APAP introduction was performed during wakefulness under continuous monitoring of blood pressure. Initial pressure support was set to 5e12 cm H 2 O, unless the treating physician decided differently on the basis of individual clinical and demographic data (eg, massive obesity, which was not present in the vast majority of patients included ( 
Adaptive servoventilation
Adaptive servoventilation (AutoSet CS2; ResMed) is a bi-level ventilation mode that changes pressure support to maintain target minute ventilation. Adaptive servoventilation was initiated during wakefulness under continuous monitoring of blood pressure. During a titration study using polysomnography, end expiratory pressure was manually adjusted to eliminate obstruction of the upper airways. Data on treatment efficacy and usage were collected from the device at follow-up visits (Res Scan; ResMed).
Echocardiography
Determination of the dimensions of the left atrium (LAD) and left ventricle (end-diastolic, LVEDD), biplane measurement of the left ventricular ejection fraction (LVEF) and estimation of systolic pulmonary artery pressure (sPAP) were performed (Vivid 7; GE Healthcare, Munich, Germany) following American Society of Echocardiography guidelines. 16 
Cardiopulmonary exercise testing
Symptom-limited bicycle cardiopulmonary exercise testing (ZAN Ferraris, Oberthulba, Germany) starting with 10 W and an increase of 10 W/min was performed at baseline and during each follow-up visit. Peak oxygen consumption (VO 2 peak), oxygen consumption at the individual aerobiceanaerobic threshold (VO 2 -AT), the relationship between minute ventilation and CO 2 production (VE/VCO 2 ), maximum workload and total exercise time were recorded. The predicted VO 2 peak was calculated taking gender and age into account.
Six-minute walk test
A 6-min walk test was performed according to American Thoracic Society (ATS) guidelines. 17 
Standard laboratory measurement
Measurementd of haemoglobin (Hb) concentration, high sensitive C-reactive protein, potassium, creatinine and N-terminal pro-brain natriuretic peptide (NT-proBNP) were performed at baseline and during follow-up visits.
Capillary blood gas analysis
Prior to CPAP introduction, the pCO 2 , partial pressure of O 2 (pO 2 ), capillary pH and base excess were taken from hyperaemic ear lobe samples and measured using an ABL 330 (Radiometer, Copenhagen, Denmark). 
Rebreathing test
The hyperoxic, hypercapnic ventilatory response testing (ZAN Ferraris) protocol is based on the Read rebreathing testing protocol. 18 Hyperoxic, HCVR sensitivity was determined as the slope of minute ventilation (l/min) plotted against PET CO 2 (mm Hg).
Statistics
Statistical analysis was performed with the Statview (Version 5.1) software (SAS Institute), and the SigmaPlot (Version 11) software. Differences between the OSA and complexSA group were compared by unpaired t test if testing for normal distribution (KolmogoroveSmirnov) passed, and with the help of the ManneWhitney test, if testing failed. In the case of categorial variables, c 2 tests or the Fisher exact test was performed. A multiple logistic regression analysis including age, sex, body mass index (BMI), LVEF, VO 2 peak, Hb concentration and hyperoxic, hypercapnic ventilatory response was conducted for recognising independent associations with complexSA. Changes from baseline to follow-up within the treatment group were analysed using the paired t test if testing for normal distribution passed, and with the help of the Wilcoxon test if testing failed. A value of p<0.05 was considered significant for all comparisons. Data are given as mean6SD unless stated otherwise.
RESULTS

Patients' characteristics
Of 192 patients with CHF with moderate to severe OSA undergoing CPAP titration, 34 (18%) developed complexSA. Though prevalence tended to be higher in those studied by polygraphy (27/141, 19%) compared with polysomnography (7/51, 14%), the c 2 test did not reveal a significant difference. An additional 36 patients (19%) presented with mild central sleep apnoea (AHI 5e14/h), which was not considered a criterion for discontinuing CPAP therapy. Demographic and clinical data are included in table 1. Patients with complexSA had lower diastolic blood pressure, a lower rate of diuretic use and a higher NYHA classification than patients with OSA. They also had higher pH and lower pCO 2 on capillary blood gas analysis, a higher VE/VCO 2 slope during cardiopulmonary exercise testing and higher hyperoxic, hypercapnic ventilatory response. Adjusted for clinical and demographic parameters including age, sex, BMI, LVEF, VO 2 peak and Hb concentration, an independent association between hyperoxic, hypercapnic ventilatory response and complexSA (p¼0.01; table 2) was found.
Adaptive servoventilation
Adaptive servoventilation was offered to all 34 patients with complexSA. Four patients (12%) refused to start treatment, and 
DISCUSSION
This is the first cohort study of patients with CHF and complexSA. A high prevalence of complexSA was found in a cohort of patients with CHF who have OSA undergoing CPAP titration. In addition, increased respiratory sensitivity to CO 2 was independently associated with complexSA Treatment with adaptive servoventilation was associated with significant improvements in control of complexSA, cardiac function and exercise tolerance. The potential importance of OSA in the pathogenesis and prognosis of CHF is increasingly recognised, and the most recent guidelines of the European Heart Failure Society recommend routine screening and treatment of OSA in patients with CHF. 9 CSA also is very common in patients CHF, 2 3 and is caused by respiratory instability occurring as a result of heart disease. 5e7 In the presence of an unstable upper airway, mixtures of obstructive and central apnoea may be observed. Some patients display a mixture of obstructive and central events during sleep, 19 and the predominant type of event may change during the night. 20 Others may display obstructive events during sleep but develop CSA when obstruction of the upper airways is treated with CPAP, a condition labelled complexSA.
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ComplexSA has been the subject of a number of studies involving patients with OSA enrolled from sleep laboratory populations but has not previously been studied in a CHF population. Javaheri recently reported an overall incidence of 6.5% in a large-scale retrospective analysis (84/1286), whereas Morgenthaler reported a prevalence of 15% (34/223 patients), Lehman 13% (13/99) and Yaegashi 6% (18/297). 21e24 The definition of complexSA used in this study was considerably more demanding than in previously published series in that the threshold AHI was 15/h as opposed to 5/h. The prevalence of 18% observed in this study accompanied by an additional 19% of patients presenting with a central AHI of >5/h during CPAP introduction suggests that complexSA is considerably more common in CHF than in sleep laboratory populations with OSA, and that with increased numbers of patients with CHF being screened and treated for OSA it will be an increasing clinical problem. CO 2 homeostasis in OSA is characterised by transient hypercapnia or eucapnia. This contrasts with the dominant CO 2 homeostasis in patients with CheyneeStokes respiration: these patients present with a highly sensitive hypocapnia-induced apnoeic threshold, whereby apnoea is initiated by small transient reductions in partial pressure of arterial carbon dioxide (PaCO 2 ). 2 25 The difference between eupnoeic PaCO 2 and the apnoeic threshold is determined by the ventilatory increase required to produce a given reduction in PaCO 2 (plant gain) and the ventilatory responsiveness to a given change in CO 2 mediated through chemoreceptors (controller gain). 26 27 The interactions of these components of the respiratory control system also seem to determine the individual predisposition to complexSA.
CHF causes a number of changes in ventilatory control including circulatory delay and enhanced chemoreceptor sensitivity.
5e7 Circulatory delay causes a delay in ventilatory responsiveness of the chemoreceptors and predisposes for CheyneeStokes respiration. 28 Indirect measures of circulatory delay, such as LVEF, tended to be lower among our complexSA cohort but did not turn out to be significant. In contrast, direct measures of the controller gain revealed an enhanced ventilatory responsiveness among patients with complexSA compared with those with pure OSA. Furthermore, the hyperoxic, hypercapnic ventilatory response was associated with complexSA even after adjustment for clinical, demographic and cardiac measures. A highly responsive chemoreceptor also predisposes to central apnoeas and periodic breathing by moving eupnoeic CO 2 closer to the apnoea threshold. Patients with complexSA thus presented with lower daytime pCO 2 . These Findings contribute to the proposed pathophysiological model of CSA as a control dysfunctionrelated disease. However, hyperoxic, hypercapnicventilatory response testing is not routinely employed in clinical practice.
Hence, identifying complex SA at the time of CPAP titration is challenging.
Adaptive servoventilation is a novel ventilatory mode which treats CSA more effectively than oxygen, CPAP or bi-level positive airway pressure. 29 30 It is in extensive clinical use for the treatment of CSA in CHF, and most, 30 31 but not all 32 published series show an improvement in CHF severity associated with its use. However, data on the long-term effect on mortality or morbidity are lacking, and are the subject of an ongoing study. 15 There are fewer publications on the use of adaptive servoventilation in complexSA. Allam and co-workers demonstrated adaptive servoventilation to be most effective in reducing AHI and arousals among 63 patients with complexSA compared with CPAP and bi-level positive airway pressure. 33 A small study showed similar results in nine patients with complexSA. 34 A recent randomised, controlled trial also displayed superiority of adaptive servoventilation compared with CPAP in patients with CHF with co-existing obstructive and central events. 19 In this study adaptive servoventilation effectively suppressed CSA, and the improvements in cardiac function were of similar magnitude to those found in previously published studies of CSA in CHF. 31 In the absence of a control arm it is impossible to ascribe these changes to adaptive servoventilation therapy. As our therapy group consisted of 27 patients only, some parameters (eg, 6 min walk distance, VE/VCO 2 slope) tended to improve but did not reach a level of significance. A large-scale, randomised, controlled study will be necessary to verify these results.
ComplexSA without CHF frequently resolves with CPAP therapy after 1e3 months, probably because elevated sensitivity to CO 2 and a narrow CO 2 reserve return to normal after days to weeks of CPAP treatment. 24 35 Over the course of adaptive servoventilation treatment there was an improvement in CO 2 sensitivity among our CHF cohort with complexSA but it remained greater than the baseline values of the group who had OSA. Whether these patients can be encouraged to continue CPAP use and be assured that CSA is transitory or should generally be switched to adaptive servoventilation treatment for an underlying tendency to respiratory instability remains to be clarified in future studies.
Limitations
The major limitation of this study is that patients with complexSA were not randomised to other treatments besides adaptive servoventilation. This is because it was not planned as a randomised, controlled therapy trial. As this is the first study ever investigating complexSA in patients with CHF, we also focused on the prevalence and predictors for complexSA in this cohort. However, changes in heart failure severity in the treatment group may be due to factors other than adaptive servoventilation therapy.
Most of our sleep studies were performed by polygraphy, not polysomnography, and AHI was derived from total recording time rather than total sleep time. This may have introduced a bias, although there is close correlation between results from the device used for polygraphy and polysomnography. 36 We defined complex sleep apnoea as $15 episodes of central apnoeas or periodic breathing per hour of sleep during CPAP administration exclusive of a significant proportion ($10%) of obstructive or mixed apnoeas or hypopnoeas. This definition is quite strict compared with others. 23 24 CPAP introduction was performed by APAP devices, which in not recommended in patients with CHF. 37 However, to avoid overtitration, we applied restrictive pressure settings at therapy introduction (5e12 cm H 2 O) which were further reduced if central events occurred. In addition, pressure levels applied were comparable with those of a recently published randomised, controlled trial involving similar patient cohorts. 19 
Summary
Beside a comparatively high prevalence, the main finding of this study is the documentation of a respiratory instability as a possible underlying mechanism of complexSA, which is veiled by recurrent upper airway obstructions. Thus, CPAP restores a 'normal' respiratory breathing pattern, which in terms of patients with complexSA means more efficient CO 2 excretion with a subsequent fall of pCO 2 below the apnoea threshold. Consequently we could confirm a higher hyperoxic, hypercapnic ventilatory response independently associated with complexSA. Adaptive servoventilation therapy proved not only to suppress complexSA effectively but also to have positive effects on subjective and objective cardiac functional parameters and to improve respiratory stability in our cohort. Whether similar effects could have emerged from ongoing CPAP therapy needs to be determined by future head-to-head comparisons. 
